LAEKNA-B (02105) Surges Over 9% Again as Breast Cancer Drug Candidate LAE002 Secures 2.045 Billion Yuan BD Deal

Stock News11-17

LAEKNA-B (02105) rose over 9% again, with a 6.71% increase at the time of writing, trading at HK$14.32 and a turnover of HK$92.66 million.

On November 12, LAEKNA licensed the China rights for its breast cancer drug candidate LAE002 (afuresertib) to Qilu Pharmaceutical in a deal worth 2.045 billion yuan. Additionally, LAEKNA is entitled to receive tiered sales royalties ranging from 10% to over 20%.

LAE002 is one of only two AKT inhibitors globally in late-stage clinical development for breast and prostate cancer. Public data shows that LAE002 is a potent AKT inhibitor targeting all three AKT isoforms (AKT1, AKT2, and AKT3). In HR+/HER2- breast cancer, its global development progress is second only to AstraZeneca's Capivasertib.

According to brokerage research, LAE002's peak domestic sales are estimated at around 2 billion yuan, while its global peak sales could mirror Capivasertib's projections. Capivasertib is expected to generate $700–800 million in sales this year, with peak sales projected at $1–2 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194686074?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 14:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194686074","market":"hk","top_or_hot":-1,"title":"LAEKNA-B (02105) Surges Over 9% Again as Breast Cancer Drug Candidate LAE002 Secures 2.045 Billion Yuan BD Deal","media":"Stock News","content":"<p>LAEKNA-B (02105) rose over 9% again, with a 6.71% increase at the time of writing, trading at HK$14.32 and a turnover of HK$92.66 million.</p>\n<p>On November 12, LAEKNA licensed the China rights for its breast cancer drug candidate LAE002 (afuresertib) to Qilu Pharmaceutical in a deal worth 2.045 billion yuan. Additionally, LAEKNA is entitled to receive tiered sales royalties ranging from 10% to over 20%.</p>\n<p>LAE002 is one of only two AKT inhibitors globally in late-stage clinical development for breast and prostate cancer. Public data shows that LAE002 is a potent AKT inhibitor targeting all three AKT isoforms (AKT1, AKT2, and AKT3). In HR+/HER2- breast cancer, its global development progress is second only to AstraZeneca's Capivasertib.</p>\n<p>According to brokerage research, LAE002's peak domestic sales are estimated at around 2 billion yuan, while its global peak sales could mirror Capivasertib's projections. Capivasertib is expected to generate $700–800 million in sales this year, with peak sales projected at $1–2 billion.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LAEKNA-B (02105) Surges Over 9% Again as Breast Cancer Drug Candidate LAE002 Secures 2.045 Billion Yuan BD Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLAEKNA-B (02105) Surges Over 9% Again as Breast Cancer Drug Candidate LAE002 Secures 2.045 Billion Yuan BD Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-17 14:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LAEKNA-B (02105) rose over 9% again, with a 6.71% increase at the time of writing, trading at HK$14.32 and a turnover of HK$92.66 million.</p>\n<p>On November 12, LAEKNA licensed the China rights for its breast cancer drug candidate LAE002 (afuresertib) to Qilu Pharmaceutical in a deal worth 2.045 billion yuan. Additionally, LAEKNA is entitled to receive tiered sales royalties ranging from 10% to over 20%.</p>\n<p>LAE002 is one of only two AKT inhibitors globally in late-stage clinical development for breast and prostate cancer. Public data shows that LAE002 is a potent AKT inhibitor targeting all three AKT isoforms (AKT1, AKT2, and AKT3). In HR+/HER2- breast cancer, its global development progress is second only to AstraZeneca's Capivasertib.</p>\n<p>According to brokerage research, LAE002's peak domestic sales are estimated at around 2 billion yuan, while its global peak sales could mirror Capivasertib's projections. Capivasertib is expected to generate $700–800 million in sales this year, with peak sales projected at $1–2 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1194686074","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194686074","pubTimestamp":1763362581,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LAEKNA-B (02105) rose over 9% again, with a 6.71% increase at the time of writing, trading at HK$14.32 and a turnover of HK$92.66 million. On November 12, LAEKNA licensed the China rights for its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02105":"来凯医药-B"},"translate_title":"乳腺癌候选药物LAE002获20.45亿元BD交易，LAEKNA-B(02105)再度大涨超9%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":1},"content_text":"LAEKNA-B (02105) rose over 9% again, with a 6.71% increase at the time of writing, trading at HK$14.32 and a turnover of HK$92.66 million.\nOn November 12, LAEKNA licensed the China rights for its breast cancer drug candidate LAE002 (afuresertib) to Qilu Pharmaceutical in a deal worth 2.045 billion yuan. Additionally, LAEKNA is entitled to receive tiered sales royalties ranging from 10% to over 20%.\nLAE002 is one of only two AKT inhibitors globally in late-stage clinical development for breast and prostate cancer. Public data shows that LAE002 is a potent AKT inhibitor targeting all three AKT isoforms (AKT1, AKT2, and AKT3). In HR+/HER2- breast cancer, its global development progress is second only to AstraZeneca's Capivasertib.\nAccording to brokerage research, LAE002's peak domestic sales are estimated at around 2 billion yuan, while its global peak sales could mirror Capivasertib's projections. Capivasertib is expected to generate $700–800 million in sales this year, with peak sales projected at $1–2 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194686074","isCrawlerRequest":true}